ACADIA Pharmaceuticals Inc.
ACAD
M
|
$17.09
1.18%
1.17%
980K
|
Health Technology
(0.0% 1d) (-9.8% 1m) (-12.8% 1y) (0.0% 2d) (0.0% 3d) (-4.7% 7d) (-14.2% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 2,815,945,294
http://www.acadia-pharm.com
Sec Filling | Patents | 503 employees
(US) ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
nervous system parkinson msa treatment
add to watch list Paper trade email alert is off
Press-releases
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-01 (Crawled : 23:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: -1.78%
conference pharmaceuticals
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: -0.35%
H: 2.16%
C: -1.76%
day pharmaceuticals
Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: 2.34%
H: 0.0%
C: -4.36%
conference health care pharmaceuticals
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
Published: 2024-02-27 (Crawled : 23:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: 0.54%
H: 2.0%
C: 1.23%
year pharmaceuticals financial results
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Published: 2024-02-13 (Crawled : 00:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: -2.58%
H: 1.29%
C: -1.96%
year pharmaceuticals financial results
Acadia Announces Additions to Executive Team - Jan 31, 2024
Published: 2024-01-31 (Crawled : 10:00) - biospace.com/
INBX | $34.64 -0.29% -0.29% 210K
|
Health Technology
|
| O: -0.36%
H: 0.57%
C: -0.21%
EXEL 4 | $22.83 0.57% 0.57% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.55%
C: -0.78%
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: -0.71%
H: 0.71%
C: -2.74%
Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: 1.76%
H: 1.23%
C: -0.14%
conference pharmaceuticals
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published: 2023-12-19 (Crawled : 22:00) - prnewswire.com
SNYNF | $92.966 -2.18% 630
|
Health Technology
|
| O: -0.39%
H: 1.49%
C: 0.32%
SUPN | $29.39 -2.0% -2.04% 390K
|
Health Technology
|
| O: -0.11%
H: 0.82%
C: -2.31%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
AXSM | $68.78 0.84% 0.83% 470K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -4.03%
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: -0.17%
H: 0.76%
C: -3.42%
therapeutics growth study market
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Published: 2023-12-18 (Crawled : 11:00) - prnewswire.com
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: -0.28%
H: 3.05%
C: 1.82%
trial
Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation
Published: 2023-12-13 (Crawled : 20:00) - biospace.com/
ACAD M | $17.09 1.18% 1.17% 980K
|
Health Technology
|
| O: 1.56%
H: 34.6%
C: 32.42%
nuplazid patent pharmaceuticals
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Last 48 Hours Insiders Buying
KFS P 481 | $8.6 1.06% 0.0% 15K
|
Finance
|
20:30
AINC | $4.83 -1.43% -1.04% 81K
|
Finance
|
20:30
RVP P 3587 | $1.065 -1.39% 0.47% 49K
|
Health Technology
|
17:00
TPL P 12 | $586.93 0.52% 0.0% 50K
|
Miscellaneous
|
16:01
HNRA | $2.76 16.95% -1.81% 400K
|
n/a
|
15:02
TGEN | $0.67 39.71% 16K
|
Utilities
|
14:30
RMCF | $3.6492 -7.2% 9.2K
|
Consumer Non-Durables
|
20:10